Being a Life Sciences Leader

Adrian Rawcliffe, Adaptimmune

Life Sciences Pennsylvania Season 7 Episode 6

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 29:14

Send a text

This episode features Adrian (Ad) Rawcliffe, CEO, Adaptimmune, recipient of the Life Sciences PA 2024 Patient Impact Award.

Ad shares the story behind TECELRA - the first FDA approved engineered cell therapy for a solid tumor. Learn about the journey leading up to this groundbreaking approval, the challenges of bringing a cell therapy to market and the next steps for Adaptimmune in the landscape of tumor treatments.